Pancreatic Cancer
Conditions
Brief summary
To investigate the correlation between pretreatment ADC value of diffusion MRI and pathologic response in patients with borderline resectable pancreatic carcinoma who undergo neoadjuvant therapy.
Detailed description
Aim: The prediction using diffusion-weighted MRI of the response evaluation in borderline resectable pancreatic cancer. Study design: Single institution. Single arm. Prospective Phase II Study. Number of case: 28 Patients: The prediction using dMRI of the response evaluation in borderline resectable pancreatic carcinoma (BRPC) in neoadjuvant therapy. Disease: Pancreatic carcinoma Method: To investigate the correlation between pretreatment ADC value of diffusion MRI and pathologic response in patients with borderline resectable pancreatic carcinoma who undergo neoadjuvant therapy. The correlation between pretreatment ADC value of diffusion MRI and pathologic response evaluated by Evans grade in patients with borderline resectable pancreatic carcinoma (BRPC) who undergo neoadjuvant therapy. 1. The correlation between pretreatment ADC value at the abutment site of BRPC and the rate of tumor cell destruction. 2. The correlation between posttreatment ADC value at the abutment site of BRPC and the rate of tumor cell destruction. 3. The correlation between the ratio of posttreatment/pretreatment ADC value at the abutment site of BRPC and the rate of tumor cell destruction. 4. The correlation between pretreatment ADC value of BRPC tumor in a largest diameter and the rate of tumor cell destruction. 5. The correlation between the ratio of posttreatment/pretreatment ADC value of BRPC tumor in a largest diameter and the rate of tumor cell destruction. 6. ADC Cut-off value which predict more than 50% and less than 10% in tumor cell destruction rate. 7. The correlation between the ratio of posttreatment/pretreatment ADC value of BRPC tumor in a largest diameter and the ratio of posttreatment/pretreatment SUV max. 8. ADC Cut-off value and SUV max cut-off value which predict survival time after surgery more than 2 years and less than 2 years. 9. The comparison of the accuracy of prediction for pathological diagnosis at abutment site between the ratio of posttreatment/pretreatment ADC value and CT scan. 10. Three correlation between high ADC value/low ADC value/the ratio of posttreatment/pretreatment ADC value and survival time after surgery. 11. Three correlation between high ADC value/low ADC value/the ratio of posttreatment/pretreatment ADC value and decreasing rate of CA19-9 value. 12. The correlation between tumor's limb sign in diffusion MRI and the rate of tumor cell destruction more than 10%.
Interventions
Diffusion MRI Patients undergo MRI within 3 weeks before start of neoadjuvant therapy/ 5 weeks after the last dose. The setting of MRI scans for b-values is 0, 50, 1000 s/mm2. The same MRI (the MRI system/scanner Intera Achieva 3.0T from Philips Medical Systems) in the independent institution is used for all patients analyzed on this study. The region of interest is determined by consensus between two experienced MR radiologists in a largest diameter based on images of abdominal CT scans avoiding the vascular area on the image of ADC map. The mean ADC values for each tumor are automatically calculated on the image of ADC map using a tomographic software program.
Sponsors
Wakayama Medical University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
The patients with borderline resectable pancreatic cancer who is expexted to undergo neoadjuvant therapy and subsequent radical surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The statistical analysis of the correlation between pretreatment ADC value of diffusion MRI and pathologic response evaluated by Evans grade in patients with borderline resectable pancreatic carcinoma (BRPC) who undergo neoadjuvant therapy. | The time duration of examinations between pretreatment diffusion MRI and histopathological examination is approximately 4 months. |
Secondary
| Measure | Time frame |
|---|---|
| The statistical analysis of the correlation between posttreatment ADC value at the abutment site of BRPC and the rate of tumor cell destruction. | The time duration of examinations between pretreatment diffusion MRI and histopathological examination is approximately 4 months. |
| The statistical analysis of the correlation between the ratio of posttreatment/pretreatment ADC value at the abutment site of BRPC and the rate of tumor cell destruction. | The time duration of examinations between pretreatment diffusion MRI and histopathological examination is approximately 4 months. |
| The statistical analysis of the correlation between pretreatment ADC value of BRPC tumor in a largest diameter and the rate of tumor cell destruction. | The time duration of examinations between pretreatment diffusion MRI and histopathological examination is approximately 4 months. |
| The statistical analysis of the correlation between the ratio of posttreatment/pretreatment ADC value of BRPC tumor in a largest diameter and the rate of tumor cell destruction. | The time duration of examinations between pretreatment diffusion MRI and histopathological examination is approximately 4 months. |
| The statistical analysis by ROC curve to investigate ADC Cut-off value which predict more than 50% and less than 10% in tumor cell destruction rate. | The time duration of examinations between pretreatment diffusion MRI and histopathological examination is approximately 4 months. |
| The statistical analysis of the correlation between pretreatment ADC value at the abutment site of BRPC and the rate of tumor cell destruction. | The time duration of examinations between pretreatment diffusion MRI and histopathological examination is approximately 4 months. |
| The statistical analysis by ROC curve to investigate ADC Cut-off value and SUV max cut-off value which predict survival time after surgery more than 2 years and less than 2 years. | Five years after initial therapy. |
| The statistical analysis of the comparison of the accuracy of prediction for pathological diagnosis at abutment site between the ratio of posttreatment/pretreatment ADC value and CT scan. | The time duration of examinations between pretreatment diffusion MRI and histopathological examination is approximately 4 months. |
| Three correlation between high ADC value/low ADC value/the ratio of posttreatment/pretreatment ADC value and survival time after surgery. | The time duration of examinations between pretreatment diffusion MRI and histopathological examination is approximately 4 months. |
| The statistical analysis of the correlation between high ADC value/low ADC value/the ratio of posttreatment/pretreatment ADC value and decreasing rate of CA19-9 value. | The time duration of examinations between pretreatment diffusion MRI and histopathological examination is approximately 4 months. |
| The statistical analysis of the correlation between tumor's limb sign in diffusion MRI and the rate of tumor cell destruction more than 10%. | The time duration of examinations between pretreatment diffusion MRI and histopathological examination is approximately 4 months. |
| The statistical analysis of the correlation between the ratio of posttreatment/pretreatment ADC value of BRPC tumor in a largest diameter and the ratio of posttreatment/pretreatment SUV max in PET-CT. | The time duration of examinations between pretreatment diffusion MRI and histopathological examination is approximately 4 months. |
Countries
Japan
Outcome results
None listed